Stockreport

Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions [Seeking Alpha]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF CEO Pablo Legorreta stated that "2025 was truly a landmark year for Royalty Pharma as we executed successfully towards our goal to be the premier capital allocator in l [Read more]